iTOL-101

A Potential Breakthrough for Type 1 Diabetes

iTOL-101 utilizes allogeneic cadaveric pancreatic islets in combination with iTOL-100 and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, insulin-dependent Diabetes, pancreatic islet cells derived from cadavers co-implanted with iTOL-100 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression.

Program Highlights:

Compelling Results Demonstrated in Non-Human Primate (NHP Study Published in Science Advances With iTOL-100

iTOL-100 combined with NHP cadaveric donor islets implanted into an NHP model of Type 1 Diabetes has shown long-term graft function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression in a preclinical study.

How iTOL-100 is Designed to Work

Even with Insulin Treatment, There Remains a Significant Unmet Need in Type 1 Diabetes

Type 1 Diabetes is a chronic condition in which the pancreas produces little or no insulin. People with brittle Diabetes frequently experience large swings in blood sugar that can quickly move from too high to too low or vice versa. Severely low blood sugar, called hypoglycemia, can cause sudden and unexpected seizures, coma, heart attacks, and even death.

1.6 million

adult patients over the age of 20 in U.S.³

$800K – $1.7M

average costs of patient treatment
for the payer⁵